Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 9.03%.

  • Anika Therapeutics' EBITDA Margin rose 897600.0% to 9.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.61%, marking a year-over-year increase of 832500.0%. This contributed to the annual value of 47.72% for FY2024, which is 203000.0% up from last year.
  • Anika Therapeutics' EBITDA Margin amounted to 9.03% in Q3 2025, which was up 897600.0% from 9.29% recorded in Q2 2025.
  • Anika Therapeutics' 5-year EBITDA Margin high stood at 2151.74% for Q4 2023, and its period low was 98.8% during Q3 2024.
  • For the 5-year period, Anika Therapeutics' EBITDA Margin averaged around 104.94%, with its median value being 9.29% (2025).
  • As far as peak fluctuations go, Anika Therapeutics' EBITDA Margin soared by 20134600bps in 2023, and later crashed by -22267300bps in 2024.
  • Over the past 5 years, Anika Therapeutics' EBITDA Margin (Quarter) stood at 17.29% in 2021, then soared by 900bps to 138.28% in 2022, then surged by 1456bps to 2151.74% in 2023, then tumbled by -103bps to 74.99% in 2024, then surged by 88bps to 9.03% in 2025.
  • Its last three reported values are 9.03% in Q3 2025, 9.29% for Q2 2025, and 16.02% during Q1 2025.